Drug Profile, Screen With Reflex to Quantitation, Serum or Plasma
Ordering Recommendation
Use to monitor patient compliance. This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.
New York DOH Approval Status
Specimen Required
Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA).
Remove plasma from cells ASAP or within 2 hours of collection. Transfer 4 mL plasma to an ARUP standard transport tube. (Min: 3 mL) Also acceptable: Serum.
Refrigerated.
Specimens exposed to repeated freeze/thaw cycles. Separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate). Hemolyzed specimens.
Cocaine and cocaethylene are more stable in fluoride-preserved plasma than serum.
After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years
Methodology
Qualitative Enzyme-Linked Immunosorbent Assay (ELISA)/Quantitative Gas Chromatography-Mass Spectrometry (GC-MS)/Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun-Sat
Reported
1-2 days
If reflexed, add 1-8 days.
Reference Interval
Drugs Covered and Cutoff Concentrations |
|
---|---|
Drugs/Drug Classes |
Screen |
Amphetamines | Effective August 17, 2020 20 ng/mL |
Methamphetamine | Effective August 17, 2020 20 ng/mL |
Barbiturates | Effective August 17, 2020 50 ng/mL |
Benzodiazepines | Effective August 17, 2020 50 ng/mL |
Buprenorphine | 1 ng/mL |
Cannabinoids | Effective August 17, 2020 20 ng/mL |
Cocaine | Effective August 17, 2020 20 ng/mL |
Methadone | Effective August 17, 2020 25 ng/mL |
Opiates | Effective August 17, 2020 20 ng/mL |
Oxycodone | Effective August 17, 2020 20 ng/mL |
Phencyclidine | Effective August 17, 2020 10 ng/mL |
Test Number |
Components |
Reference Interval |
---|---|---|
Buprenorphine Screen, S/P | Methodology: Immunoassay Positive Cutoff: 1 ng/mL | |
Methamphetamine Screen, S/P | Methodology: Immunoassay Positive Cutoff: 20 ng/mL | |
Oxycodone/Oxymorphone Screen, S/P | Methodology: Immunoassay Positive Cutoff: 20 ng/mL | |
Methadone Screen, S/P | Methodology: Immunoassay Positive Cutoff: 25 ng/mL | |
Benzodiazepines Screen, S/P | Methodology: Immunoassay Positive Cutoff: 50 ng/mL | |
Barbiturates Screen, S/P | Methodology: Immunoassay Positive Cutoff: 50 ng/mL | |
Amphetamines Screen, S/P | Methodology: Immunoassay Positive Cutoff: 20 ng/mL | |
Phencyclidine Screen, S/P | Methodology: Immunoassay Positive Cutoff: 10 ng/mL | |
Opiates Screen, S/P | Methodology: Immunoassay Positive Cutoff: 20 ng/mL | |
Cocaine Screen, S/P | Methodology: Immunoassay Positive Cutoff: 20 ng/mL | |
Carboxy-THC Screen, S/P | Methodology: Immunoassay Positive Cutoff: 20 ng/mL |
Interpretive Data
Drugs/drug classes reported as "Positive" are automatically reflexed to mass spectrometry confirmation/quantitation. An unconfirmed positive immunoassay screen result may be useful for medical purposes but does not meet forensic standards. The absence of expected drug(s) and/or drug metabolite(s) may indicate noncompliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. Specimens for which drugs or drug classes are detected by the screen are automatically reflexed to a second, more specific technology (GC/MS and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
For medical purposes only; not valid for forensic use.
Laboratory Developed Test (LDT)
Note
Screen-positive specimens are automatically confirmed by GC/MS and/or LC-MS/MS; additional charges may apply.
Hotline History
CPT Codes
80307; if reflexed, add 80324; 80345; 80346; 80348; 80349; 80353; 80358; 80359; 80361; 80365; 83992 (Reflexed Alt Code: G0480 )
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
0092419 | Screen, S/P, Interpretation | 48767-8 |
0092421 | Carboxy-THC Screen, S/P | 8172-9 |
0092422 | Cocaine Screen, S/P | 8191-9 |
0092423 | Opiates Screen, S/P | 8219-8 |
0092424 | Phencyclidine Screen, S/P | 8236-2 |
0092425 | Amphetamines Screen, S/P | 8149-7 |
0092426 | Barbiturates Screen, S/P | 20421-4 |
0092427 | Benzodiazepines Screen, S/P | 46976-7 |
0092428 | Methadone Screen, S/P | 59705-4 |
0092430 | Oxycodone/Oxymorphone Screen, S/P | 13576-4 |
0093414 | Methamphetamine Screen, S/P | 3777-0 |
2013568 | Buprenorphine Screen, S/P | 3413-2 |
Aliases
- Pain Management